论文部分内容阅读
目的探讨血清CEA、CA19-9与CA72-4联合检测对结肠癌的临床应用价值。方法用电化学发光法检测40例结肠癌患者、36例结肠良性疾病患者、100例体检健康者的血清CEA、CA72-4与CA19-9含量,分析其在结肠癌诊断的价值。结果血清CEA、CA19-9与CA72-4水平显著高于结肠良性病变患者及健康体检人群的水平(P<0.05),结肠良性病变患者血清CEA、CA19-9与CA72-4浓度显著高于健康体检人群的浓度(P<0.05)。在结肠癌中联合检测阳性率明显高于单一检测。结论三种肿瘤标志物联合检测可提高结肠癌的检出率。
Objective To investigate the clinical value of combined detection of serum CEA, CA19-9 and CA72-4 on colon cancer. Methods The serum levels of CEA, CA72-4 and CA19-9 in 40 patients with colon cancer, 36 patients with benign colon disease and 100 healthy controls were detected by electrochemiluminescence. The diagnostic value of CEA, CA72-4 and CA19-9 in colon cancer was analyzed. Results Serum levels of CEA, CA19-9 and CA72-4 were significantly higher than those of patients with benign colonic lesions and healthy subjects (P <0.05). Serum concentrations of CEA, CA19-9 and CA72-4 in patients with benign colonic lesions were significantly higher than those in healthy controls Physical examination population concentration (P <0.05). The positive rate of combined detection in colon cancer was significantly higher than that of single detection. Conclusion The combined detection of three tumor markers can improve the detection rate of colon cancer.